-
EP3303590
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3303590
| EP3303590 - MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL) [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 10.05.2021 Database last updated on 03.01.2025 | |
| Former | Examination is in progress Status updated on 09.04.2019 | ||
| Former | Request for examination was made Status updated on 09.03.2018 | ||
| Former | The international publication has been made Status updated on 09.12.2016 | Most recent event Tooltip | 10.05.2021 | Application deemed to be withdrawn | published on 09.06.2021 [2021/23] | Applicant(s) | For all designated states Miragen Therapeutics, Inc. 6200 Lookout Road Boulder, Colorado 80301 / US | [2018/15] | Inventor(s) | 01 /
RODMAN, David c/o Miragen Therapeutics Inc. 6200 Lookout Road Boulder, Colorado 80301 / US | 02 /
SETO, Anita c/o Miragen Therapeutics Inc. 6200 Lookout Road Boulder, Colorado 80301 / US | 03 /
DALBY, Christina c/o Miragen Therapeutics Inc. 6200 Lookout Road Boulder, Colorado 80301 / US | 04 /
JACKSON, Aimee c/o Miragen Therapeutics Inc. 6200 Lookout Road Boulder, Colorado 80301 / US | 05 /
BEATTY, Xuan c/o Miragen Therapeutics Inc. 6200 Lookout Road Boulder, Colorado 80301 / US | [2018/15] | Representative(s) | Cooley (UK) LLP 22 Bishopsgate London EC2N 4BQ / GB | [N/P] |
| Former [2018/15] | Cooley (UK) LLP Dashwood 69 Old Broad Street London EC2M 1QS / GB | Application number, filing date | 16804580.5 | 03.06.2016 | [2018/15] | WO2016US35865 | Priority number, date | US201562171758P | 05.06.2015 Original published format: US 201562171758 P | [2018/15] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2016197024 | Date: | 08.12.2016 | Language: | EN | [2016/49] | Type: | A2 Application without search report | No.: | EP3303590 | Date: | 11.04.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 08.12.2016 takes the place of the publication of the European patent application. | [2018/15] | Search report(s) | International search report - published on: | US | 09.02.2017 | (Supplementary) European search report - dispatched on: | EP | 29.11.2018 | Classification | IPC: | C12N15/113, A61P35/00, A61K31/7088 | [2018/15] | CPC: |
C12N15/113 (EP,KR,RU,US);
A61K45/06 (KR,RU);
A61K48/00 (KR,RU);
A61P35/00 (EP,KR,RU);
A61P35/02 (EP);
A61P43/00 (EP);
C12Q1/6886 (KR,RU);
C12N2310/113 (EP,KR,US);
C12N2310/315 (EP,KR,US);
C12N2310/3231 (EP,KR,US);
C12N2310/344 (EP,KR,US);
C12N2310/3531 (KR);
| C-Set: |
C12N2310/322, C12N2310/3531 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/15] | Title | German: | MIR-155-INHIBITOREN ZUR BEHANDLUNG VON KUTANEM T-ZELL-LYMPHOM (CTCL) | [2018/15] | English: | MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL) | [2018/15] | French: | INHIBITEURS DE MIR-155 POUR LE TRAITEMENT DU LYMPHOME CUTANÉ À CELLULES T (CTCL) | [2018/15] | Entry into regional phase | 05.12.2017 | National basic fee paid | 05.12.2017 | Search fee paid | 05.12.2017 | Designation fee(s) paid | 05.12.2017 | Examination fee paid | Examination procedure | 05.12.2017 | Examination requested [2018/15] | 05.12.2017 | Date on which the examining division has become responsible | 15.03.2019 | Amendment by applicant (claims and/or description) | 12.04.2019 | Despatch of a communication from the examining division (Time limit: M04) | 03.06.2019 | Reply to a communication from the examining division | 04.07.2019 | Despatch of a communication from the examining division (Time limit: M04) | 25.09.2019 | Reply to a communication from the examining division | 06.11.2019 | Despatch of a communication from the examining division (Time limit: M04) | 09.03.2020 | Reply to a communication from the examining division | 18.06.2020 | Despatch of a communication from the examining division (Time limit: M06) | 12.01.2021 | Application deemed to be withdrawn, date of legal effect [2021/23] | 02.02.2021 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2021/23] | Fees paid | Renewal fee | 12.06.2018 | Renewal fee patent year 03 | 13.06.2019 | Renewal fee patent year 04 | 15.06.2020 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2007095387 (DHARMACON INC [US], et al) [A] 1-15 * Whole document, especially the claims and Seq ID No 189 and 526. *; | [A]WO2007112753 (SANTARIS PHARMA AS [DK], et al) [A] 1-15* Whole document, especially the claims. *; | [A]US2013236453 (CROCE CARLO M [US], et al) [A] 1-15 * Whole document, especially the claims. *; | [I] - WORM J ET AL, "Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of G-CSF", NUCLEIC ACIDS RESEARCH, INFORMATION RETRIEVAL LTD, vol. 37, no. 17, doi:10.1093/NAR/GKP577, ISSN 0305-1048, (20090901), pages 5784 - 5792, (20090713), XP002560080 [I] 1-6,8,10 * Whole document, especially page 5785, first column 2nd paragraph. * DOI: http://dx.doi.org/10.1093/nar/gkp577 | International search | [A]US2010286234 (ELMEN JOACIM [SE], et al) [A] 1-10, 17-29* entire document *; | [A]US2010298410 (OBAD SUSANA [SE], et al) [A] 1-10, 17-29 * entire document *; | [X]US2011077288 (KAUPPINEN SAKARI [DK], et al) [X] 1-10, 17-29 * para [0010], [0012], [0017], [0039], [0052], [0054]-[0059], [0062]-[0064], [0068], [0072], [0104], [0111], [0112], [0225], Tables 1, 3, SEQ ID NOs: 164, 165, 194-199 * |